Doug has forty years of experience working in operations and finance, including eight years as CEO of an ophthalmic medical device company in Dallas engaged in successful FDA studies. He has spent the last two years working on other various healthcare specialty projects
Since 2015, Doug has been involved in impact investing as a member of the core team and board member for the Lion's Den Venture Capital Conference, an organization that identifies, prepares, and strategically directs companies that have a "quadruple bottom-line" (economic, social, environmental, spiritual). Starting in 2016, the Lion's Den has sponsored five events showcasing over fifty companies in their efforts to raise early stage capital from Kingdom investors.
Among other executive roles, Doug was President and CEO of Refocus Group, Inc., for eight years starting in 2005. Refocus Group is an early stage medical device company, backed by venture capital, which specializes in surgeries for the treatment of certain ophthalmic conditions including presbyopia and glaucoma.